Assessment of objective ambulation in lower extremity sarcoma patients with a continuous activity monitor

Rationale and validation

Kenneth Gundle, Stephanie E. Punt, Ernest U. Conrad

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In addition to patient reported outcome measures, accelerometers may provide useful information on the outcome of sarcoma patients treated with limb salvage. The StepWatch (SW) Activity Monitor (SAM) is a two-dimensional accelerometer worn on the ankle that records an objective measure of walking performance. The purpose of this study was to validate the SW in a cross-sectional population of adult patients with lower extremity sarcoma treated with limb salvage. The main outcome was correlation of total steps with the Toronto Extremity Salvage Score (TESS). In a sample of 29 patients, a mean of 12 days of SW data was collected per patient (range 6-16), with 2767 average total steps (S.D. 1867; range 406-7437). There was a moderate positive correlation between total steps and TESS (r=0.56, P=0.002). Patients with osseous tumors walked significantly less than those with soft tissue sarcoma (1882 versus 3715, P<0.01). This study supports the validity of the SAM as an activity monitor for the objective assessment of real world physical function in sarcoma patients.

Original languageEnglish (US)
Article number947082
JournalSarcoma
Volume2014
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Sarcoma
Walking
Lower Extremity
Limb Salvage
Extremities
Ankle
Population
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Assessment of objective ambulation in lower extremity sarcoma patients with a continuous activity monitor : Rationale and validation. / Gundle, Kenneth; Punt, Stephanie E.; Conrad, Ernest U.

In: Sarcoma, Vol. 2014, 947082, 01.01.2014.

Research output: Contribution to journalArticle

@article{1e4cb57245004a41ab662ce52aaad968,
title = "Assessment of objective ambulation in lower extremity sarcoma patients with a continuous activity monitor: Rationale and validation",
abstract = "In addition to patient reported outcome measures, accelerometers may provide useful information on the outcome of sarcoma patients treated with limb salvage. The StepWatch (SW) Activity Monitor (SAM) is a two-dimensional accelerometer worn on the ankle that records an objective measure of walking performance. The purpose of this study was to validate the SW in a cross-sectional population of adult patients with lower extremity sarcoma treated with limb salvage. The main outcome was correlation of total steps with the Toronto Extremity Salvage Score (TESS). In a sample of 29 patients, a mean of 12 days of SW data was collected per patient (range 6-16), with 2767 average total steps (S.D. 1867; range 406-7437). There was a moderate positive correlation between total steps and TESS (r=0.56, P=0.002). Patients with osseous tumors walked significantly less than those with soft tissue sarcoma (1882 versus 3715, P<0.01). This study supports the validity of the SAM as an activity monitor for the objective assessment of real world physical function in sarcoma patients.",
author = "Kenneth Gundle and Punt, {Stephanie E.} and Conrad, {Ernest U.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1155/2014/947082",
language = "English (US)",
volume = "2014",
journal = "Sarcoma",
issn = "1357-714X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Assessment of objective ambulation in lower extremity sarcoma patients with a continuous activity monitor

T2 - Rationale and validation

AU - Gundle, Kenneth

AU - Punt, Stephanie E.

AU - Conrad, Ernest U.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In addition to patient reported outcome measures, accelerometers may provide useful information on the outcome of sarcoma patients treated with limb salvage. The StepWatch (SW) Activity Monitor (SAM) is a two-dimensional accelerometer worn on the ankle that records an objective measure of walking performance. The purpose of this study was to validate the SW in a cross-sectional population of adult patients with lower extremity sarcoma treated with limb salvage. The main outcome was correlation of total steps with the Toronto Extremity Salvage Score (TESS). In a sample of 29 patients, a mean of 12 days of SW data was collected per patient (range 6-16), with 2767 average total steps (S.D. 1867; range 406-7437). There was a moderate positive correlation between total steps and TESS (r=0.56, P=0.002). Patients with osseous tumors walked significantly less than those with soft tissue sarcoma (1882 versus 3715, P<0.01). This study supports the validity of the SAM as an activity monitor for the objective assessment of real world physical function in sarcoma patients.

AB - In addition to patient reported outcome measures, accelerometers may provide useful information on the outcome of sarcoma patients treated with limb salvage. The StepWatch (SW) Activity Monitor (SAM) is a two-dimensional accelerometer worn on the ankle that records an objective measure of walking performance. The purpose of this study was to validate the SW in a cross-sectional population of adult patients with lower extremity sarcoma treated with limb salvage. The main outcome was correlation of total steps with the Toronto Extremity Salvage Score (TESS). In a sample of 29 patients, a mean of 12 days of SW data was collected per patient (range 6-16), with 2767 average total steps (S.D. 1867; range 406-7437). There was a moderate positive correlation between total steps and TESS (r=0.56, P=0.002). Patients with osseous tumors walked significantly less than those with soft tissue sarcoma (1882 versus 3715, P<0.01). This study supports the validity of the SAM as an activity monitor for the objective assessment of real world physical function in sarcoma patients.

UR - http://www.scopus.com/inward/record.url?scp=84920506950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920506950&partnerID=8YFLogxK

U2 - 10.1155/2014/947082

DO - 10.1155/2014/947082

M3 - Article

VL - 2014

JO - Sarcoma

JF - Sarcoma

SN - 1357-714X

M1 - 947082

ER -